A phase 3 clinical trial (PRESENT) studied the efficacy of E75 co-administration with granulocyte-macrophage colony-stimulating factor (GM-CSF) immunoadjuvant in preventing breast cancer recurrence in an adjuvant setting [81]. This evidence concerns the gene CSF2 and breast cancer.